Vitrolife AB (CHIX:VITRS) ROCE % : 4.19% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Vitrolife AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vitrolife AB's annualized ROCE % for the quarter that ended in Mar. 2024 was 4.19%.

Vitrolife AB ROCE % Historical Data

The historical data trend for Vitrolife AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vitrolife AB ROCE % Chart

Vitrolife AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

28.44

18.12

4.56

3.03

-20.27

Vitrolife AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															3.17	3.63	3.46	-91.17	4.19

Vitrolife AB ROCE % Calculation

Vitrolife AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-3618	/	( ( (20551 - 621)	+	(16329 - 557) )	/ 2 )
	=	-3618	/	( (19930	+	15772)	/ 2 )
	=	-3618	/	17851
	=	-20.27 %

Vitrolife AB's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	672	/	( ( (16329 - 557)	+	(16873 - 556) )	/ 2 )
	=	672	/	( ( 15772	+	16317 )	/ 2 )
	=	672	/	16044.5
	=	4.19 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Vitrolife AB (CHIX:VITRs) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vitrolife AB ROCE % Related Terms

Thank you for viewing the detailed overview of Vitrolife AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Vitrolife AB (CHIX:VITRS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vitrolife AB (CHIX:VITRs) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

VITR:Sweden 0YAY:UK VTFN:Germany

Address

Box 9080, Gothenburg, SWE, 400 92

Website

https://www.vitrolife.com

Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive advanced support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction.

Vitrolife AB (CHIX:VITRS) Headlines

No Headlines